The yeast infection treatment market has seen considerable growth due to a variety of factors.
• The market for treating yeast infections has seen robust growth in recent years. From 2024 to 2025, the market is projected to expand from $4.33 billion to $4.65 billion, corresponding to a Compound Annual Growth Rate (CAGR) of 7.5%.
This vigorous growth in the historic period is linked to several factors: a rising number of yeast infection cases, heightened knowledge about fungal infections, an aging population, a global increase in healthcare spending, and the approval and development of novel antifungal drugs.
The yeast infection treatment market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations indicate a significant expansion in the yeast infection treatment market in the forthcoming years, with an estimated value of $5.85 billion in 2029 and a compound annual growth rate (CAGR) of 5.9%.
Predicted growth during the projection period is tied to an increase in telemedicine usage for offsite consultations, individualized medicine strategies for specific treatments, the advent of combined therapies for improved efficacy, an escalating concentration on natural and herbal solutions, as well as a central focus on microbiome-centric therapies to combat infection. Noteworthy trends within this period will comprise advances in genomic research, the creation of compact and precise diagnostic devices, technological evolution in yeast infection diagnosis and treatment, heightened investment in research and development, as well as strategic alliances.
The expected surge in autoimmune diseases is predicted to fuel the upward movement of the yeast infection treatment market. An autoimmune illness is characterized by the immune system erroneously attacking healthy cells, tissues, and organs, thereby impairing body functions and possibly posing a risk to life. Yeast infection remedies play a key role in managing and preventing autoimmune-associated complications by addressing recurring yeast infections associated with certain autoimmune disorders. They could also potentially sway the immune response through the control of fungal infections in patients grappling with autoimmune disorders. In March 2023, it was foreseen by the National Institutes of Health, a US-based federal body that conducts and supports medical research, that there would be approximately 8.4 million people worldwide with type 1 diabetes (T1DM) in 2021 with an addition of 500,000 new cases in that year. Moreover, the projected population afflicted by T1DM is anticipated to range between 13.5 and 17.4 million by 2040. Hence, the escalating prevalence of autoimmune diseases is pushing the advancement of the yeast infection treatment market.
The yeast infection treatment market covered in this report is segmented –
1) By Type: Powders, Creams Or Ointments, Tablets Or Capsules, Other Types
2) By Treatment: Medical Treatment, Surgery
3) By Indication: Genital Candidiasis, Invasive Candidiasis, Oropharyngeal Or Esophageal Candidiasis (Thrush), Other Indications
4) By Route Of Administration: Oral, Topical, IV (Intravenous) Or IM (Intramuscular), Other Routes Of Administration
5) By Application: Retail Pharmacies Or Drug Stores, Hospital Pharmacies, Specialty Stores, Online Sales, Other Applications
Subsegments:
1) By Powders: Antifungal Powders, Medicated Body Powders
2) By Creams Or Ointments: Antifungal Creams, Vaginal Ointments, Topical Creams
3) By Tablets Or Capsules: Oral Antifungal Tablets, Probiotic Capsules, Vaginal Tablets
4) By Other Types: Suppositories, Sprays, Gels
Key players in the yeast infection treatment market are making strategic moves such as rolling out new medications or solutions, like non-azole oral antifungals, to secure a competitive advantage. Non-azole oral antifungals are medicines consumed orally to combat fungal infections, but they are not part of the azole group of antifungals. For example, in December 2022, SCYNEXIS, an American biotech firm, received approval from the US Food and Drug Administration (FDA) for the second indication for their product BREXAFEMME (ibrexafungerp tablets). This innovative non-azole oral antifungal, the first of its kind approved by the FDA, is used for treating vaginal yeast infections, also called vulvovaginal candidiasis (VVC), and decreasing the probability of VVC recurrence. This game-changing solution offers broad-spectrum action, thereby influencing the yeast infection treatment market trends and providing previously unavailable options to patients suffering from recurrent VVC. The suggested daily intake of BREXAFEMME to treat VVC consists of 300 mg (two 150 mg tablets), administered twice a day, approximately 12 hours apart, resulting in a total sum of 600 mg (four 150 mg tablets).
Major companies operating in the yeast infection treatment market report are:
• Pfizer Inc.
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis International AG
• Sanofi SA
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• AstraZeneca PLC
• Bayer AG
• Astellas Pharma Inc.
• Torrent Pharmaceuticals
• Catalent Inc.
• bioMérieux SA
• Cipla
• Bruker Corporation
• Brundavan Laboratories Private Limited
• Glenmark Pharmaceuticals Ltd
• Zydus Lifesciences
• Prestige Consumer Healthcare Inc.
• CordenPharma International
• Synmedic Laboratories
• Basilea Pharmaceutica AG
• Jubilant Pharmova Limited
• Curia Global Inc.
• Synexis LLC
• Manus Aktteva Biopharma LLP
North America was the largest region in the yeast infection treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the yeast infection treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.